Introduction to Allergic Airway Disease

The incidence of allergic airway illnesses has seen a notable escalation in recent decades, affecting around 30 percent of the population in affluent nations. The global prevalence of this condition is estimated to impact over 315 million individuals, with around 10% of asthma sufferers experiencing severe or uncontrolled symptoms. In the setting of airway allergies, immunological responses develop upon initial encounters with allergens in a manner associated with type 2 helper T-cell (Th2) functioning. The aforementioned procedure leads to the expression of interleukin (IL)-4, IL-5, and IL-13 inflammatory proteins, as well as the production of allergen-specific antibodies known as immunoglobulin E (IgE) at heightened levels. Efficient treatment techniques are required for the control and management of allergic disorders. Medicinal interventions for respiratory conditions include the use of bronchodilators and inhaled corticosteroids, which have demonstrated efficacy in mitigating inflammation and alleviating associated symptoms. However, it is important to note that these medications are unable to alter the inherent nature and course of the disease. Therefore, the need is crucial to clarify the shared major physiological variables and biological mechanisms driving AADs, because any therapy that targets these “master switches” is better than the standard approach.